Celgene Corp.’s psoriasis drug Otezla (apremilast) is expected to become a blockbuster seller this year, surpassing sales of $1bn, management said during the company’s second quarter sales and earnings call July 28. The drug would become the company’s fourth blockbuster franchise and the first outside of Celgene’s specialty in oncology.
Otezla generated sales of $242m in the quarter, a 170% increase over the second quarter a year ago. The oral...







